What question did this study set out to answer?

Investigate the impact of different treatment eras on the development of therapy-related malignancies in multiple myeloma patients.

December 8, 2025Blood

Therapy-related malignancies in myeloma: SEER comparison of IMiD vs anti-CD38 eras

View Full Paper

Ask AI

Bookmark

Authors

Population-based analysis shows reduced mortality and SPM in myeloma patients treated with anti-CD38, highlighting evolving treatment impacts.

Investigate the impact of different treatment eras on the development of therapy-related malignancies in multiple myeloma patients.
Utilized SEER-17 database to assess secondary primary malignancy (SPM) development among 3,641 multiple myeloma patients.
Compared outcomes across IMiD (2006–2012) and anti-CD38 (2015–2021) treatment periods.
Analyzed demographic characteristics and mortality using chi-square tests.
1,494 SPMs occurred in the anti-CD38 era compared to 2,147 in the IMiD era.
Mortality decreased from 73% in the IMiD era to 43% in the anti-CD38 era.
The proportion of patients with multiple SPMs declined from 11.8% to 9.2% between eras.

Patel et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Population-based analysis shows reduced mortality and SPM in myeloma patients treated with anti-CD38, highlighting evolving treatment impacts.